-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Frontline Treatment of Newly Diagnosed, Transplant-Ineligible Multiple Myeloma Across Patient Types

Sponsor: Janssen Biotech, Inc
Program: Product Theaters
Monday, December 12, 2022: 12:15 PM-1:15 PM
Hall J - Theater 5 (Ernest N. Morial Convention Center)
Annelore Cortoos, MD, Janssen Biotech, Inc.
No relevant conflicts of interest to declare.
This presentation is intended for U.S. based registered meeting attendees

For in-person participants only

See more of: Product Theaters